Evidence map›Paper›PMID 27076853›Full record

ArticleJournal of Cancer2016

CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.

Yi-Ying Lee, Wen-Jeng Wu, Chun-Nung Huang, Ching-Chia Li, Wei-Ming Li, Bi-Wen Yeh, Peir-In Liang, Ting-Feng Wu, Chien-Feng Li

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Bioinformatics Analysis of the Expression of Key Long Intergenic Non-Protein Coding RNA Genes in Bladder Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. OncoTargets and therapy · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Yi-Ying Lee1. Department of Pathology, Chi Mei Medical Center, Liouying, Tainan, Taiwan;
Wen-Jeng Wu2. Department of Urology, Faculty of Medicine, Kaohsiung Medical University;; 3. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;; 4. Department of Urology, Kaohsiung Municipal Ta-Tung Hospital;; 5. Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Chun-Nung Huang2. Department of Urology, Faculty of Medicine, Kaohsiung Medical University;; 3. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;; 5. Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Ching-Chia Li2. Department of Urology, Faculty of Medicine, Kaohsiung Medical University;; 3. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;; 4. Department of Urology, Kaohsiung Municipal Ta-Tung Hospital;; 5. Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Wei-Ming Li2. Department of Urology, Faculty of Medicine, Kaohsiung Medical University;; 3. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;; 5. Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Bi-Wen Yeh2. Department of Urology, Faculty of Medicine, Kaohsiung Medical University;; 3. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;; 5. Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Peir-In Liang7. Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University;
Ting-Feng Wu8. Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan;
Chien-Feng Li8. Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan;; 9. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan;; 10. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; 11. Division of Clinical Pathology, Chi Mei Medical Center, Tainan, Taiwan.
Chi Mei Medical Center · TWKaohsiung Medical University · TWKaohsiung Municipal Ta-Tung Hospital · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWNational Health Research Institutes · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrothelial carcinoma (UC) commonly occurs in the urinary bladder (UB) and rarely in upper the upper urinary tract (UT). Its molecular pathogenesis, however, remains obscure. Though the constitutive phosphorylation of Signal Transducer and Activator of Transcription 5 (STAT5) is an important part of carcinogenesis generally, researchers have not systematically investigated this process specifically in relation to UC. The present study addresses this gap. Through data mining a published transcriptomic database of UBUCs (GSE32894), it identified Colony Stimulating Factor 2 (CSF2) as the stepwise upregulated gene of much significance among those related to the positive regulation of tyrosine phosphorylation of STAT5 (GO:0042523). Since the phosphorylation of STAT5, a key process in the development of UC, is closely associated with CSF2, we then examine CSF2 transcript and protein expression, justifying their association with clinicopathological features and survival in our well-established cohort of patients with UC.

designLaser capture microdissection in conjunction with real-time qRT-PCR are used to detect CSF2 transcript levels in 24 UBUCs and 6 non-tumor urothelium samples. We then used the H-score method to evaluate the immunohistochemistry in order to determine CSF2 protein expression in 296 UBUCs and 340 UTUCs, respectively. After correlating protein expression status with key clinicopathological features, the prognostic significance of CSF2 protein expression was determined for disease-specific survival (DSS) and metastasis-free survival (MeFS).

resultsWe exclusively detected the CSF2 transcript, which was stepwise upregulated in tumor lesions (p=0.010). In both groups of UC we found overexpression of CSF2 significantly related to incremental pT status (UTUC, p=0.011; UBUC, p<0.001), as well as with perineural invasion (UTUC, p=0.002; UBUC, p=0.001). Univariate analysis found a close correlation between CSF2 overexpression and unfavorable prognosis for both DSS (UTUC, p=0.0001; UBUC, p<0.0001) and MeFS (UTUC, p=0.0001; UBUC, p=0.0002). High expression of CSF2 still remained prognostically for DSS (UTUC, p=0.015; UBUC, p=0.004) and MeFS (UTUC, p=0.008; UBUC, p=0.027) in multivariate comparison.

conclusionOur data showed that overexpression of CSF2 was inferred in advanced disease status and poor clinical outcomes for both UTUC and UBUC patients, suggesting that CSF2 may serve as an important prognosticator and a potential therapeutic target of UC.

Indexed as

Colony Stimulating Factor 2CSF2upper tracturinary bladderurothelial carcinoma.

Identifiers

PMID27076853
PMCPMC4829558
OpenAlexW2328382193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.